Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.27) by 7.41 percent. This is a 13.79 percent increase over losses of $(0.29) per share from the same period last year. The company reported quarterly sales of $2.082 million which beat the analyst consensus estimate of $1.366 million by 52.43 percent. This is a 9.18 percent increase over sales of $1.907 million the same period last year.